NPS Pharmaceuticals, Inc.
(
NPSP
) reported fourth quarter 2012 net loss per share of 14 cents,
wider than the Zacks Consensus Estimate of a loss of 9 cents and
the year-ago loss of 10 cents. The wider loss was primarily
attributable to higher expenses.
Fourth quarter 2012 revenues climbed 3.5% to $27.2 million.
Revenues constitute of royalties as well as milestones and
license fees. Revenues were below the Zacks Consensus Estimate of
$29 million.
In the fourth quarter of 2012 research and development
expenses were $24 million, up 11.1%. The increase was
attributable to higher personnel-related expenses incurred during
the final quarter of 2012. In 2012 general and administrative
expenses were $11.2 million, up 55.5%.
Full year 2012 net loss per share was 22 cents compared with
45 cents of loss per share in 2011. The Zacks Consensus Estimate
for 2012 hinted at a net loss of 16 cents per share. Revenues in
2012 increased 28.5% year over year to $130.6 million. Revenues
for 2012 missed the Zacks Consensus Estimate of $134 million.
We note that the company received encouraging news during the
final quarter of 2012 when the US Food and Drug Administration
(FDA) approved Gattex® (teduglutide). The drug was cleared for
the treatment of adults with short bowel syndrome (SBS), who are
dependent on a parenteral support.
NPS Pharma is also developing Natpara (rhPTH[1-84]) for the
treatment of adult hypoparathyroidism and expects to submit its
Biologic License Application (BLA) to the FDA in the second half
of 2013.
2013 Guidance
Total operating expenses, including share-based compensation
are expected in the range $135 million to $145 million in
2013.
NPS carries a Zacks Rank #3 (Hold). Currently, companies like
Lannett Company, Inc.
(
LCI
),
SIGA Technologies, Inc.
(
SIGA
) and
United Therapeutics Corporation
(
UTHR
) look more attractive with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
NPS PHARMA INC (NPSP): Free Stock Analysis
Report
SIGA TECH INC (SIGA): Free Stock Analysis
Report
UTD THERAPEUTIC (UTHR): Free Stock Analysis
Report
To read this article on Zacks.com click here.
Zacks Investment
Research